K. Ogiwara

发表

Emicizumab enhances thrombus formation in vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease

K. Nogami, M. Shima, T. Kitazawa, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance.

D. Hampshire, J. Goudemand, C. Halldén, 2018, Blood advances.

Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population

W. Hopman, D. Lillicrap, I. Pabinger, 2020, Journal of thrombosis and haemostasis : JTH.

Genetic determinants of VWF clearance and FVIII-binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.

V. Blanchette, M. Carcao, W. Hopman, 2019, Blood.

A novel simultaneous clot‐fibrinolysis waveform analysis for assessing fibrin formation and clot lysis in haemorrhagic disorders

Tomoko Matsumoto, K. Nogami, M. Shima, 2019, British journal of haematology.

Optimal monitoring of bypass therapy in hemophilia A patients with inhibitors by the use of clot waveform analysis

K. Nogami, M. Shima, K. Ogiwara, 2014, Journal of thrombosis and haemostasis : JTH.

Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor

Tomoko Matsumoto, K. Nogami, M. Shima, 2014, International Journal of Hematology.

A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies

Tomoko Matsumoto, K. Nogami, M. Shima, 2012, Thrombosis and Haemostasis.

Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII

K. Nogami, M. Shima, K. Ogiwara, 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A

Tomoko Matsumoto, K. Nogami, M. Shima, 2009, International journal of hematology.

New assays for monitoring haemophilia treatment

Tomoko Matsumoto, M. Shima, K. Ogiwara, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

The scavenger receptor SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen

K. Tryggvason, D. Lillicrap, J. Lai, 2019, Journal of thrombosis and haemostasis : JTH.

Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms

P. James, W. Hopman, D. Lillicrap, 2016, Journal of thrombosis and haemostasis : JTH.

The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19

H. Yoshiji, S. Muro, K. Tsuruya, 2022, International Journal of Hematology.

A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X

K. Nogami, M. Shima, T. Soeda, 2020, International Journal of Hematology.

Correlations between global clotting function tests, duration of operation, and postoperative chest tube drainage in pediatric cardiac surgery

Y. Hayata, Tomoko Matsumoto, M. Shima, 2011, Paediatric anaesthesia.

Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients

K. Nogami, M. Shima, M. Takeyama, 2022, International Journal of Hematology.

Comprehensive coagulation and fibrinolytic potential in the acute phase of pediatric patients with idiopathic nephrotic syndrome evaluated by whole blood-based rotational thromboelastometry

K. Nogami, K. Ogiwara, Tomoaki Ishikawa, 2022, Pediatric Nephrology.

A microchip flow‐chamber assay screens congenital primary hemostasis disorders

K. Nogami, M. Shima, K. Ogiwara, 2020, Pediatrics international : official journal of the Japan Pediatric Society.

Whole blood ristocetin‐induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease

K. Nogami, M. Shima, K. Ogiwara, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Emicizumab improves the stability and structure of fibrin clot derived from factor VIII‐deficient plasma, similar to the addition of factor VIII

Tomoko Matsumoto, K. Nogami, M. Shima, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Hemostatic assessment of combined anticoagulant therapy using warfarin and prothrombin complex concentrates in a case of severe protein C deficiency

S. Ohga, K. Nogami, M. Shima, 2019, International Journal of Hematology.

Screening of the protein C pathway abnormality‐related thrombophilia by using thrombomodulin‐mediated tissue factor‐triggered clot waveform analysis

K. Nogami, M. Takeyama, K. Ogiwara, 2022, European journal of haematology.

Characterization of thrombophilia-related plasmas evaluated by anticoagulants-mediated thrombin and plasmin generation assays

K. Nogami, M. Takeyama, K. Ogiwara, 2022, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden.

Tomoko Matsumoto, K. Nogami, K. Amano, 2014, Blood.

Factor VIII activation by factor VIIa analog (V158D/E296V/M298Q) in tissue factor-independent mechanisms

K. Nogami, M. Shima, K. Ogiwara, 2011, Thrombosis and Haemostasis.

A Novel Assessment of Factor VIII Activity by Template Matching Utilizing Weighted Average Parameters from Comprehensive Clot Waveform Analysis

K. Nogami, M. Shima, K. Ogiwara, 2020, Thrombosis and Haemostasis.

The Factor VIIIa C2 Domain (Residues 2228–2240) Interacts with the Factor IXa Gla Domain in the Factor Xase Complex*

Y. Sakata, K. Nogami, M. Shima, 2009, Journal of Biological Chemistry.

Comprehensive genetic screening for vascular Ehlers–Danlos syndrome through an amplification‐based next‐generation sequencing system

Kyoko Takano, M. Sumi, N. Koitabashi, 2022, American journal of medical genetics. Part A.

Successful prophylaxis using activated prothrombin complex concentrates (aPCC) in a severe haemophilia A patient with inhibitor previously unresponsive to on‐demand daily infusions of aPCC

K. Nogami, M. Shima, K. Ogiwara, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage

K. Nogami, M. Takeyama, K. Ogiwara, 2022, International Journal of Hematology.

Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system

K. Nogami, M. Shima, M. Takeyama, 2019, International Journal of Hematology.

Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip‐based flow chamber system

Tomoko Matsumoto, K. Nogami, M. Shima, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry

K. Nogami, M. Shima, K. Ogiwara, 2015, Journal of thrombosis and haemostasis : JTH.

Hemostatic function in hyperfibrinolytic disseminated intravascular coagulation

K. Nogami, M. Shima, M. Yamazaki, 2019, Pediatrics international : official journal of the Japan Pediatric Society.

Effects of anti-factor VIII inhibitor antibodies on factor VIIa/tissue factor-catalysed activation and inactivation of factor VIII

K. Nogami, M. Shima, K. Ogiwara, 2011, Thrombosis and Haemostasis.

Anti‐idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab

K. Nogami, M. Shima, T. Soeda, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial

K. Nogami, M. Taki, K. Amano, 2022, BMJ Open.

Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan

Tomoko Matsumoto, K. Nogami, M. Shima, 2021, International journal of hematology.

Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis

K. Nogami, M. Shima, M. Takeyama, 2019, International Journal of Hematology.

Activated prothrombin complex concentrate (APCC)‐mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness

K. Nogami, M. Shima, K. Ogiwara, 2013, Journal of thrombosis and haemostasis : JTH.

Hemostatic Treatment Using Factor VIII Concentrates for Neutralizing High-Responding Inhibitors Prior to CVAD Insertion for Immune-Tolerance Induction Therapy

Tomoko Matsumoto, M. Shima, J. Giddings, 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report

K. Nogami, M. Shima, Yasuhito Tanaka, 2018, International Journal of Hematology.

Activated partial thromboplastin time-based clot waveform analysis enables measurement of very low levels of factor IX activity in patients with severe hemophilia B

K. Nogami, M. Takeyama, K. Ogiwara, 2022, International Journal of Hematology.

Clot waveform analysis using CS‐2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A

K. Nogami, M. Shima, K. Ogiwara, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

First report of real-time monitoring of coagulation function potential and IgG subtype of anti-FVIII autoantibodies in a child with acquired hemophilia A associated with streptococcal infection and amoxicillin

Tomoko Matsumoto, K. Nogami, M. Shima, 2017, International Journal of Hematology.

Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A

K. Nogami, M. Shima, M. Takeyama, 2021, Thrombosis and Haemostasis.

Basic aspect of emicizumab

K. Nogami, K. Ogiwara, 2022, Japanese Journal of Thrombosis and Hemostasis.

Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI‐deficient plasma in vitro

K. Nogami, M. Shima, T. Kitazawa, 2018, Journal of thrombosis and haemostasis : JTH.

Successful perioperative haemostatic management of aortic coarctation in a 5‐week‐old infant with severe haemophilia A

K. Nogami, M. Shima, K. Ogiwara, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Assessment of Emicizumab-Driven Clot Stability in Hemophilia a Model

K. Nogami, M. Shima, T. Kitazawa, 2018, Blood.

Assessing the clinical severity of type 1 von Willebrand disease patients with a microchip flow‐chamber system

K. Nogami, M. Shima, K. Hosokawa, 2016, Journal of thrombosis and haemostasis : JTH.

Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti‐C2 antibody inhibiting allogeneic but not autologous factor VIII activity

K. Nogami, M. Shima, H. Wakabayashi, 2015, Journal of thrombosis and haemostasis : JTH.

Role of red blood cells in the anemia‐associated bleeding under high shear conditions

K. Nogami, M. Shima, K. Hosokawa, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Use of a microchip flow-chamber system as a screening test for platelet storage pool disease

K. Nogami, M. Shima, K. Hosokawa, 2015, International Journal of Hematology.

Modified expi293 cell culture system using piggyBac transposon enables efficient production of human FVIII

K. Nogami, M. Shima, K. Horie, 2022, International Journal of Hematology.

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

Tomoko Matsumoto, K. Nogami, M. Shima, 2018, Blood.

Successful management of Mallory‐Weiss syndrome in a haemophilia A patient with inhibitor by recombinant activated factor VII

M. Shima, A. Yoshioka, I. Tanaka, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII

M. Ozelo, D. Lillicrap, C. Hough, 2015, Molecular therapy. Methods & clinical development.

Factor (F)VIII/VIIa enhances global haemostatic function in the co‐presence of bypassing agents and FVIII among patients with haemophilia A with inhibitor

Tomoko Matsumoto, K. Nogami, M. Shima, 2018, British journal of haematology.

Inhibitor Index in the Clot Waveform Analysis-Based Mixing Test Differentiates among Hemophilia A without and with Inhibitors, and Lupus Anticoagulant

K. Nogami, M. Shima, K. Ogiwara, 2021, Thrombosis and Haemostasis.

Interactions between residues 2228–2240 within factor VIIIa C2 domain and factor IXa Gla domain contribute to propagation of clot formation

K. Nogami, M. Shima, T. Soeda, 2011, Thrombosis and Haemostasis.

A case of a young boy with hyper-fibrinolysis associated with natural fibrin precipitates suspected to have occurred through a novel coagulation and fibrinolysis mechanism

Tomoko Matsumoto, K. Nogami, K. Ogiwara, 2022, International Journal of Hematology.

Mechanisms of human neutrophil elastase-catalysed inactivation of factor VIII(a)

Tomoko Matsumoto, K. Nogami, M. Shima, 2011, Thrombosis and Haemostasis.

A new drug delivery system for intravenous coronary thrombolysis with thrombus targeting and stealth activity recoverable by ultrasound.

Yasuhiko Tabata, Yoshihiko Saito, Hiroyuki Kawata, 2012, Journal of the American College of Cardiology.

Regulation of coagulation factors during liver regeneration in mice: mechanism of factor VIII elevation in plasma.

Kohei Tatsumi, Teruo Okano, T. Okano, 2011, Thrombosis research.

Protein S down‐regulates factor Xase activity independent of activated protein C: specific binding of factor VIII(a) to protein S inhibits interactions with factor IXa

K. Nogami, M. Shima, A. Yoshioka, 2008, British journal of haematology.

High levels of factor VIII activity in patients with acquired hemophilia A in remission are associated with unusually low coagulation potentials

K. Nogami, M. Takeyama, K. Ogiwara, 2023, International Journal of Hematology.

Intra‐articular haemorrhage caused by reduced recovery of PEGylated recombinant factor VIII due to an anti‐PEG antibody developed after mRNA‐1273 SARS‐CoV‐2 vaccination in haemophilia A

K. Nogami, M. Takeyama, K. Ogiwara, 2023, Haemophilia : the official journal of the World Federation of Hemophilia.

Potential role of activated factor VIII (FVIIIa) in FVIIa/tissue factor-dependent FXa generation in initiation phase of blood coagulation

K. Nogami, M. Shima, K. Ogiwara, 2019, International Journal of Hematology.

Mechanisms of factor VIIa‐catalyzed activation of factor VIII

Tomoko Matsumoto, K. Nogami, M. Shima, 2010, Journal of thrombosis and haemostasis : JTH.

Identification of Plasmin-interactive Sites in the Light Chain of Factor VIII Responsible for Proteolytic Cleavage at Lys36*

K. Nogami, M. Shima, A. Yoshioka, 2009, Journal of Biological Chemistry.

Determination of a factor VIII-interactive region within plasmin responsible for plasmin-catalysed activation and inactivation of factor VIII(a)

K. Nogami, M. Shima, K. Okada, 2010, Thrombosis and Haemostasis.

Identification of a protein S-interactive site within the A2 domain of the factor VIII heavy chain

K. Nogami, M. Shima, M. Takeyama, 2009, Thrombosis and Haemostasis.

Impaired factor V-related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations.

K. Nogami, M. Takeyama, K. Horie, 2023, Blood advances.

Blood coagulation dynamics during adrenocorticotropic hormone therapy in pediatric patients with infantile spasms

K. Nogami, K. Ogiwara, T. Sakakibara, 2022, Brain and Development.

Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A

K. Nogami, M. Takeyama, T. Soeda, 2023, Pediatric blood & cancer.

Decrease in in vivo coagulant potential of emicizumab in a patient with hemophilia A and inhibitor complicated with infectious mononucleosis.

M. Shima, Tomomi Niino, M. Takeyama, 2022, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis

K. Nogami, M. Shima, M. Takeyama, 2023, International Journal of Hematology.

Pediatric Mesangial Proliferative Glomerulonephritis Has Increased the Platelet Thrombus Formation Potentials under High-Shear Flow Condition

K. Ogiwara, Takashi Omae, Keiji Nogami, 2023, Nephron.

Anticoagulant effects of protein C, protein S, and antithrombin levels on the protein C pathway in young children

K. Ogiwara, T. Nishikubo, H. Tonegawa, 2024, International journal of hematology.

Force‐sensing treadmill gait analysis system can detect gait abnormalities in haemophilia patients without arthropathy

M. Shima, K. Ogiwara, Yuya Mawarikado, 2024, Haemophilia : the official journal of the World Federation of Hemophilia.